ODonnell P, Buhl D, Johannesen J, Lijffijt M
Adv Neurobiol. 2024; 40:45-65.
PMID: 39562440
DOI: 10.1007/978-3-031-69491-2_2.
Stahl A, Heider J, Wust R, Fallgatter A, Schenke-Layland K, Volkmer H
BMC Psychiatry. 2024; 24(1):757.
PMID: 39482642
PMC: 11526604.
DOI: 10.1186/s12888-024-06127-x.
Xue L, Zhao J, Liu X, Zhao T, Zhang Y, Ye H
Epigenetics. 2024; 19(1):2417158.
PMID: 39460980
PMC: 11520555.
DOI: 10.1080/15592294.2024.2417158.
Palmisano A, Pandit S, Smeralda C, Demchenko I, Rossi S, Battelli L
Life (Basel). 2024; 14(5).
PMID: 38792599
PMC: 11122172.
DOI: 10.3390/life14050578.
Uliana D, Lisboa J, Gomes F, Grace A
Biochem Pharmacol. 2024; 228:116298.
PMID: 38782077
PMC: 11410545.
DOI: 10.1016/j.bcp.2024.116298.
The AMPK-related kinase NUAK1 controls cortical axons branching by locally modulating mitochondrial metabolic functions.
Lanfranchi M, Yandiev S, Meyer-Dilhet G, Ellouze S, Kerkhofs M, Dos Reis R
Nat Commun. 2024; 15(1):2487.
PMID: 38514619
PMC: 10958033.
DOI: 10.1038/s41467-024-46146-6.
Parvalbumin interneuron deficits in schizophrenia.
Marin O
Eur Neuropsychopharmacol. 2024; 82:44-52.
PMID: 38490084
PMC: 11413553.
DOI: 10.1016/j.euroneuro.2024.02.010.
N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia.
Romero-Miguel D, Casquero-Veiga M, Lamanna-Rama N, Torres-Sanchez S, MacDowell K, Garcia-Partida J
Transl Psychiatry. 2024; 14(1):14.
PMID: 38191622
PMC: 10774365.
DOI: 10.1038/s41398-023-02652-7.
Visual cortex repetitive transcranial magnetic stimulation (rTMS) reversing neurodevelopmental impairments in adolescents with major psychiatric disorders (MPDs): A cross-species translational study.
Liu J, Guo H, Yang J, Xiao Y, Cai A, Zhao T
CNS Neurosci Ther. 2023; 30(3):e14427.
PMID: 37721197
PMC: 10915985.
DOI: 10.1111/cns.14427.
Towards a youth mental health paradigm: a perspective and roadmap.
Uhlhaas P, Davey C, Mehta U, Shah J, Torous J, Allen N
Mol Psychiatry. 2023; 28(8):3171-3181.
PMID: 37580524
PMC: 10618105.
DOI: 10.1038/s41380-023-02202-z.
Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment.
De Simone G, Mazza B, Vellucci L, Barone A, Ciccarelli M, de Bartolomeis A
Antioxidants (Basel). 2023; 12(4).
PMID: 37107350
PMC: 10135787.
DOI: 10.3390/antiox12040975.
Behavioral regulation by perineuronal nets in the prefrontal cortex of the CNTNAP2 mouse model of autism spectrum disorder.
Gandhi T, Liu C, Adeyelu T, Canepa C, Lee C
Front Behav Neurosci. 2023; 17:1114789.
PMID: 36998537
PMC: 10043266.
DOI: 10.3389/fnbeh.2023.1114789.
A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages.
Mayeli A, Clancy K, Sonnenschein S, Sarpal D, Ferrarelli F
Psychiatry Res. 2023; 317:114926.
PMID: 36932470
PMC: 10729941.
DOI: 10.1016/j.psychres.2022.114926.
Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study.
Wang M, Barker P, Cascella N, Coughlin J, Nestadt G, Nucifora Jr F
Mol Psychiatry. 2023; 28(5):2018-2029.
PMID: 36732587
PMC: 10394114.
DOI: 10.1038/s41380-023-01969-5.
Animal Models of Relevance to the Schizophrenia Prodrome.
Petty A, Howes O, Eyles D
Biol Psychiatry Glob Open Sci. 2023; 3(1):22-32.
PMID: 36712558
PMC: 9874082.
DOI: 10.1016/j.bpsgos.2021.12.001.
PlexinA1-deficient mice exhibit decreased cell density and augmented oxidative stress in parvalbumin-expressing interneurons in the medial prefrontal cortex.
Jahan M, Tsuzuki T, Ito T, Bhuiyan M, Takahashi I, Takamatsu H
IBRO Neurosci Rep. 2022; 13:500-512.
PMID: 36451778
PMC: 9703010.
DOI: 10.1016/j.ibneur.2022.11.002.
A glial perspective on the extracellular matrix and perineuronal net remodeling in the central nervous system.
Tewari B, Chaunsali L, Prim C, Sontheimer H
Front Cell Neurosci. 2022; 16:1022754.
PMID: 36339816
PMC: 9630365.
DOI: 10.3389/fncel.2022.1022754.
Chronic N-acetylcysteine treatment improves anhedonia and cognition in a mouse model of the schizophrenia prodrome.
Buhner L, Kapanaiah S, Katzel D
Front Behav Neurosci. 2022; 16:1002223.
PMID: 36225391
PMC: 9548602.
DOI: 10.3389/fnbeh.2022.1002223.
Chronic N-Acetylcysteine Treatment Prevents Amphetamine-Induced Hyperactivity in Heterozygous Mutant Mice, a Putative Prodromal Schizophrenia Animal Model.
Lai C, Baskaran R, Tsao C, Tuan L, Siow P, Palani M
Int J Mol Sci. 2022; 23(16).
PMID: 36012679
PMC: 9408838.
DOI: 10.3390/ijms23169419.
Hippocampal circuit dysfunction in psychosis.
Knight S, McCutcheon R, Dwir D, Grace A, ODaly O, McGuire P
Transl Psychiatry. 2022; 12(1):344.
PMID: 36008395
PMC: 9411597.
DOI: 10.1038/s41398-022-02115-5.